Leftagraph

Every financial statement,
one clean chart.

Search any US-listed company. Data straight from SEC filings.

PROBuild your own list with the screener

Sana Biotechnology, Inc. (SANA) financial statements

Number look wrong? Tell us

Data table
PROBuild your own list with the screener

Sana Biotechnology, Inc. (SANA), most recent 12 months reported: net loss $211.82M, free cash flow -$135.06M. Latest balance sheet on file: liquid cash $160.49M. From SEC filings. Others in Biological Products, (No Diagnostic Substances): PHARMACYTE BIOTECH, INC. · REPLIMUNE GROUP, INC. · Revolution Medicines, Inc. · SAB BIOTHERAPEUTICS, INC. · Solid Biosciences Inc. · SILEXION THERAPEUTICS CORP · SCHOLAR ROCK HOLDING CORPORATION · Protara Therapeutics, Inc.

Stock screener

Watchlist